Biotechnology Industry | Healthcare Sector | Dr. Rahul D. Ballal Ph.D. CEO | NASDAQ (NGS) Exchange | US45249V1070 ISIN |
United States Country | 6 Employees | - Last Dividend | - Last Split | - IPO Date |
IMARA Inc. is a biopharmaceutical company established with a keen focus on advancing and bringing to market novel therapeutics intended for individuals grappling with severe medical conditions. Founded in 2016, the company has positioned its headquarters in Brookline, Massachusetts. IMARA Inc. is dedicated to the discovery, development, and commercialization of innovative treatments that promise to improve the lives of patients facing serious diseases, leveraging cutting-edge science and research to tackle unmet medical needs.
IMARA Inc.'s product pipeline is primarily focused on the development of therapies aimed at treating rare and serious diseases. Although the document does not detail specific products currently offered or in development by the company, IMARA's approach generally emphasizes the following areas:
Development of groundbreaking pharmaceutical drugs designed to address the root causes of specific serious diseases. This involves a robust R&D program targeting the discovery of new drug candidates that can provide significant clinical benefits over existing treatments.
Specializing in treatments for rare diseases, which are often underserved by the broader pharmaceutical industry. This focus not only meets a critical healthcare need but also aligns with global regulatory incentives designed to encourage the development of drugs for these conditions.